Dustin A. Deming
A5048019436- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- Genetic factors in colorectal cancer
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Colorectal and Anal Carcinomas
- PI3K/AKT/mTOR signaling in cancer
- Pancreatic and Hepatic Oncology Research
- Immunotherapy and Immune Responses
- Cancer Treatment and Pharmacology
- Cancer Research and Treatments
- Cancer, Hypoxia, and Metabolism
- Lung Cancer Treatments and Mutations
- 3D Printing in Biomedical Research
- Neuroendocrine Tumor Research Advances
- Glycosylation and Glycoproteins Research
- Colorectal Cancer Surgical Treatments
- Peptidase Inhibition and Analysis
- Chronic Lymphocytic Leukemia Research
- Advanced Breast Cancer Therapies
- Neuroblastoma Research and Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Mechanisms and Therapy
- Renal cell carcinoma treatment
University of Wisconsin–Madison
2016-2025
University of Wisconsin Carbone Cancer Center
2016-2025
Wisconsin Division of Public Health
2023-2024
Center for Cancer Research
2016-2024
NRG Oncology
2023
Madison Group (United States)
2019-2021
William S. Middleton Memorial Veterans Hospital
2015-2020
Array BioPharma (United States)
2020
Ipsen (France)
2020
Promega (United States)
2020
This portion of the NCCN Guidelines for Colon Cancer focuses on use systemic therapy in metastatic disease. Considerations treatment selection among 32 different monotherapies and combination regimens up to 7 lines have included history, extent disease, goals treatment, efficacy toxicity profiles regimens, KRAS/NRAS mutational status, patient comorbidities preferences. Location primary tumor, BRAF mutation tumor microsatellite stability should also be considered decisions.
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options treatment of metastatic colorectal cancer (mCRC), because important updates have recently been made to this section. These include recommendations first-line use checkpoint inhibitors mCRC, that is deficient mismatch repair/microsatellite instability-high, related biosimilars, and expanded biomarker testing. The now targeted patients with mCRC...
The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, management of recurrent and metastatic disease, survivorship. These Insights summarize the Panel discussions 2018 update guidelines risk stratification adjuvant treatment patients with stage III colon cancer,
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Rectal Cancer address diagnosis, staging, surgical management, perioperative treatment, management of recurrent and metastatic disease, disease surveillance, survivorship patients with rectal cancer. This portion the guidelines focuses on localized which involves careful patient selection curative-intent treatment options that sequence multimodality therapy usually comprised chemotherapy, radiation, resection.
This selection from the NCCN Guidelines for Rectal Cancer focuses on management of malignant polyps and resectable nonmetastatic rectal cancer because important updates have been made to these guidelines. These recent include redrawing algorithms stage II III disease reflect new data supporting increasingly prominent role total neoadjuvant therapy, expanded recommendations short-course radiation therapy techniques, a "watch-and-wait" nonoperative technique patients with that shows complete...
The NCCN Guidelines for Rectal Cancer provide recommendations the diagnosis, evaluation, treatment, and follow-up of patients with rectal cancer. These Insights summarize panel discussion behind recent important updates to guidelines. include clarifying definition rectum differentiating from sigmoid colon; total neoadjuvant therapy approach localized cancer; biomarker-targeted metastatic colorectal cancer, a focus on new treatment options BRAF V600E- or HER2 amplification-positive disease.
Small bowel adenocarcinoma (SBA) is a rare malignancy of the gastrointestinal tract that has increased in incidence across recent years. Often diagnosed at an advanced stage, outcomes for SBA are worse on average than other related malignancies, including colorectal cancer. Due to rarity this disease, few studies have been done direct optimal treatment, although data shown responds treatment differently cancer, necessitating separate approach treatment. The NCCN Guidelines Bowel...
Cancer treatment is limited by inaccurate predictors of patient-specific therapeutic response. Therefore, some patients are exposed to unnecessary side effects and delays in starting effective therapy. A clinical tool that predicts sensitivity for individual needed.Patient-derived cancer organoids were derived across multiple histologies. The histologic characteristics, mutation profile, clonal structure, response chemotherapy radiation assessed using bright-field optical metabolic imaging...
Colorectal cancer (CRC) is the fourth most frequently diagnosed and second leading cause of death in United States. Management disseminated metastatic CRC involves various active drugs, either combination or as single agents. The choice therapy based on consideration goals therapy, type timing prior mutational profile tumor, differing toxicity profiles constituent drugs. This manuscript summarizes data supporting systemic options recommended for NCCN Guidelines Colon Cancer.
This discussion summarizes the NCCN Clinical Practice Guidelines for managing squamous cell anal carcinoma, which represents most common histologic form of disease. A multidisciplinary approach including physicians from gastroenterology, medical oncology, surgical radiation and radiology is necessary. Primary treatment perianal cancer canal are similar include chemoradiation in cases. Follow-up clinical evaluations recommended all patients with carcinoma because additional curative-intent...
The determination of an optimal treatment plan for individual patient with rectal cancer is a complex process. In addition to decisions relating the intent surgery (ie, curative or palliative), consideration must also be given likely functional results treatment, including probability maintaining restoring normal bowel function/anal continence and preserving genitourinary functions. Particularly patients distal cancer, finding balance between curative-intent therapy while having minimal...
Standard first-line therapies for metastatic colorectal cancer (mCRC) include fluoropyrimidine-containing regimens with oxaliplatin and/or irinotecan and a biologic agent. Immunotherapy may enhance antitumor activity in combination standard patients mCRC. Here, we present phase 2 results of nivolumab plus standard-of-care therapy (SOC; 5-fluorouracil/leucovorin/oxaliplatin/bevacizumab) versus SOC the treatment mCRC (CheckMate 9X8).
5 Background: For patients (pts) with colon cancer (CC), the detection of circulating tumor DNA (ctDNA) is associated persistent disease after resection and outperforms traditional clinical pathological features in prognosticating recurrence risk. We hypothesized that for pts low-risk stage II CC, a positive ctDNA status may identify those who benefit from adjuvant chemotherapy. Methods: In this prospective phase II/III trial, resected CC without high risk whom evaluating oncologist deems...
The NCCN Guidelines for Anal Carcinoma provide recommendations the management of patients with squamous cell carcinoma anal canal or perianal region. Primary treatment cancer usually includes chemoradiation, although certain lesions can be treated margin-negative local excision alone. Disease surveillance is recommended all because additional curative-intent possible. A multidisciplinary approach including physicians from gastroenterology, medical oncology, surgical radiation and radiology...
New tools are needed to match cancer patients with effective treatments. Patient-derived organoids offer a high-throughput platform personalize treatments and discover novel therapies. Currently, methods evaluate drug response in limited because they overlook cellular heterogeneity. In this study, non-invasive optical metabolic imaging (OMI) of heterogeneity was characterized breast (BC) pancreatic (PC) patient-derived organoids. Baseline analyzed for each patient, demonstrating that...
Abstract Colorectal cancer originates within immunologically complex microenvironments. To date, the benefits of immunotherapy have been modest, except in neoantigen-laden mismatch repair–deficient tumors. Approaches to enhance tumor-infiltrating lymphocytes tumor bed may substantially augment clinical responses. In this article, we report that proteolysis tolerogenic matrix proteoglycan versican (VCAN) strongly correlated with CD8+ T cell infiltration colorectal cancer, regardless repair...
8 Background: Standard 1L therapies for mCRC include a fluoropyrimidine with oxaliplatin and/or irinotecan, and biologic agent. NIVO may enhance antitumor activity in combination standard within subset of patients (pts) mCRC. CheckMate 9X8 evaluated + mFOLFOX6/BEV vs (NCT03414983). Methods: Adults previously untreated, unresectable, were randomized 2:1 to 240 mg Q2W (NIVO standard-of-care [SOC]) or (SOC). Primary endpoint was progression-free survival (PFS) assessed by blinded independent...
Activating mutations in
Gemcitabine and cisplatin has limited benefit as treatment for advanced biliary tract cancer (BTC). The addition of an anti-programmed death receptor (PD-1)/PD-ligand (L1) antibody to either systemic chemotherapy or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) shown in multiple solid tumors.In this phase 2 trial, patients 18 years older with BTC without prior therapy Eastern Cooperative Oncology Group Performance Status 0-1 were randomized across six academic centers. Patients...
Abstract Background: Mutations in KRAS are among the most frequent oncogenic drivers with G12C mutation found up to ~13% of NSCLC. LY3537982 is an oral, highly selective, and potent inhibitor G12C, which preclinically delivers >90% sustained target occupancy. We present initial results from LOXO-RAS-20001, a phase 1 study patients (pts) G12C-mutant advanced solid tumors (NCT04956640). Methods: monotherapy dose escalation followed mTPI-2 method. Dose expansion cohorts included...
94 Background: LY3537982 is an oral, potent, and highly selective inhibitor of GDP-bound KRAS G12C with unique pharmacologic properties that achieve high target occupancy at low absolute exposures. Here we present results GI tumors treated on LOXO-RAS-20001, a phase 1 study in patients (pts) mutation. Methods: Dose escalation followed mTPI-2 method. expansion included combination cetuximab colorectal cancer (CRC). All pts were naïve. Key objectives to determine the RP2D, safety, PK,...
8510 Background: While immunotherapy (IO) is established as the cornerstone of first-line treatment for KRAS-mutant NSCLC, outcomes remain suboptimal. Further progress may be achieved with addition targeted therapy to IO, an paradigm in some other cancer types (RCC), but historically challenging NSCLC. Here, we study pembrolizumab plus olomorasib, a potent and highly selective second-generation inhibitor GDP-bound KRAS G12C, NSCLC patients treated on LOXO-RAS-20001, phase 1/2 olomorasib...